<div class="modal special-interest">
    <h4>CASE 1 (OPEN-LABEL PHAa SE)<sup>a</sup></h4>
    <ul class="check">
        <li>8-year-old white female (22.1 kg) taking 7 mg tofacitinib/day. Had a mild herpes zoster infection on day 19 of the study, determined to be related to study drug. Drug was withdrawn and acylovir and gabapentin were prescribed. The infection did not clear within 10 days and the subject was terminated fr0 0 om the study and Hepatic events rolled over into the long term extension study. The infection resolved by day 46</li>
        <li>Subject did not previously have chicken pox and received the chicken pox vaccine on 6/25/2014. Did not receive shingles vaccine.</li>
    </ul>
    <h4>CASE 2 (OPEN-LABEL PHASE)</h4>
    <ul class="check">
        <li>5-year-old white female (18.1 kg) taking 7 mg tofacitinib/day. Had a mild herpes zoster infection on day 98 of the study, determined to be related to study drug. Drug was interrupted and the infection resolved by day 109.</li>
        <li>Subject had chicken pox in 2013, did not receive the chicken pox vaccine nor the shingles vaccine</li>
    </ul>
    <p class="footnote"><sup>a</sup>Both cases were mild and monodermatomal and neither case met opportunisitic infection criteria.</p>
    <button class="submit safety">
        <i class="fas fa-times"></i>
        CLOSE
    </button>
</div>

<section id="safety" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety active">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main class="dosing-adjustments">
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content">
        <a href="" ui-sref="ADVERSE-EVENTS" class="back-btn safety">
            <i class="fas fa-arrow-circle-left"></i>
            <h5 class="safety-header">BACK</h5>
        </a>
        <h3 class="safety-header">AEs OF SPECIAL INTEREST</h3>
        <div class="img-wrapper">
            <img src="assets/safety/safety-2.svg" alt="patients with events" />
        </div>
        <div class="footnotes">
            <p>Phase 3 safety data include full analysis set (pcJIA , jPsA , ERA patients included).</p>
            <ol>
                <li>
                5 mg BID or equivalent weight based lower dose in patients &lt;40 kg; </li>
                <li>Adjudicated events;</li>
                <li>Both mild and monodermatomal , and neither met opportunistic infection criteria; </li>
                <li>Both cases were mild and monodermatomal and neither case met opportunistic infection criteria</li>
                <li>three subjects in the open label run in phase had serious infections: one patient had three SIs: epidural empyema, sinusitis and subperiosteal abscess. One patient had appendicitis and one patient had pneumonia. </li>
                <li>One serious AE of pilonidal cyst repair was coded to surgical procedures instead of infections and was inadvertently not identified as a serious infection. </li>
                <li>appendicitis . Following adjudication, it was determined that the serious AE did not meet</li>
            </ol>
            <p>ATE, arterial thromboembolism; BID, twice daily; DB, double-blind; DVT, deep vein thrombosis; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis; NMSC, nonmelanoma skin cancer;
                OL, open-label; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis; PE, pulmonary embolism; SAE, serious adverse event.
            </p>
                <p>Data on file. Pfizer, Inc. 2022.</p>
        </div>
    </div>
    </main>
</div>
<nav class="mobile">
    <a href="" ui-sref="MOA" class="moa">
        <i class="fas fa-atom"></i>
        <h5>MOA</h5>
    </a>
    <a href="" ui-sref="CT" class="ct">
        <i class="fas fa-users"></i>
        <h5>Clinical Trials</h5>
    </a>
    <a href="" ui-sref="EFFICACY" class="efficacy">
        <i class="fas fa-chart-line"></i>
        <h5>Efficacy</h5>
    </a>
    <a href="" ui-sref="SAFETY" class="safety active">
        <i class="fas fa-exclamation-triangle"></i>
        <h5>Safety</h5>
    </a>
    <a href="" ui-sref="DOSING" class="dosing">
        <i class="fas fa-prescription"></i>
        <h5>Dosing</h5>
    </a>
</nav>
</section>

<script src="js/safety/special-interest/modal.js"></script>